Items Tagged ‘positive metastatic’

November 13th, 2017

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

By

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015, Alcensa received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant […]

View full entry

Tags: Alcensa, alectinib, alk, anaplastic lymphoma kinase, crizotinib, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, positive metastatic, Precision Cancer Medicine, xalkori